Apyx Medical (NASDAQ:APYX) Upgraded to Hold at Zacks Research

Zacks Research upgraded shares of Apyx Medical (NASDAQ:APYX) to a hold rating in a research note issued to investors on Tuesday morning,Zacks.com reports.

A number of other equities analysts also recently commented on APYX. Wall Street Zen downgraded shares of Apyx Medical from a “buy” rating to a “hold” rating in a research note on Sunday, April 26th. HC Wainwright started coverage on shares of Apyx Medical in a research report on Monday. They set a “buy” rating and a $7.00 price target for the company. Finally, Weiss Ratings reiterated a “sell (d-)” rating on shares of Apyx Medical in a report on Wednesday, June 24th. One analyst has rated the stock with a Strong Buy rating, four have assigned a Buy rating, one has given a Hold rating and one has assigned a Sell rating to the company. Based on data from MarketBeat, Apyx Medical presently has a consensus rating of “Moderate Buy” and an average target price of $6.60.

Apyx Medical Stock Up 4.7%

APYX opened at $4.42 on Tuesday. Apyx Medical has a 1 year low of $1.59 and a 1 year high of $5.08. The firm has a 50 day moving average price of $4.22 and a 200 day moving average price of $3.89. The company has a debt-to-equity ratio of 2.68, a quick ratio of 4.79 and a current ratio of 5.80. The company has a market cap of $185.25 million, a PE ratio of -20.09 and a beta of 1.37.

Apyx Medical (NASDAQ:APYX) last announced its quarterly earnings results on Thursday, May 7th. The company reported ($0.05) earnings per share for the quarter, beating analysts’ consensus estimates of ($0.11) by $0.06. Apyx Medical had a negative net margin of 16.40% and a negative return on equity of 88.47%. The firm had revenue of $12.49 million for the quarter, compared to analysts’ expectations of $10.53 million. Sell-side analysts expect that Apyx Medical will post -0.21 earnings per share for the current year.

Hedge Funds Weigh In On Apyx Medical

Institutional investors have recently added to or reduced their stakes in the company. Nantahala Capital Management LLC grew its stake in shares of Apyx Medical by 19.1% during the fourth quarter. Nantahala Capital Management LLC now owns 3,974,091 shares of the company’s stock valued at $13,909,000 after acquiring an additional 636,043 shares in the last quarter. Vanguard Group Inc. lifted its stake in shares of Apyx Medical by 3.6% in the third quarter. Vanguard Group Inc. now owns 1,528,947 shares of the company’s stock worth $3,272,000 after acquiring an additional 53,175 shares in the last quarter. AIGH Capital Management LLC purchased a new position in Apyx Medical in the fourth quarter valued at about $3,867,000. Silverberg Bernstein Capital Management LLC boosted its holdings in Apyx Medical by 0.8% in the first quarter. Silverberg Bernstein Capital Management LLC now owns 1,041,070 shares of the company’s stock valued at $3,842,000 after purchasing an additional 8,067 shares during the last quarter. Finally, Sei Investments Co. grew its stake in Apyx Medical by 298.6% during the 1st quarter. Sei Investments Co. now owns 598,255 shares of the company’s stock valued at $2,208,000 after purchasing an additional 448,174 shares in the last quarter. Institutional investors and hedge funds own 55.33% of the company’s stock.

Apyx Medical News Roundup

Here are the key news stories impacting Apyx Medical this week:

• Positive Sentiment: HC Wainwright kept a Buy rating on Apyx Medical and set a $7.00 price target, implying meaningful upside from current levels.
• Positive Sentiment: The firm’s forecasts show gradually improving earnings over the next several quarters, with losses expected to narrow from around ($0.06) per share in mid-2026 to about ($0.03) per share by Q4 2027.
• Neutral Sentiment: HC Wainwright’s full-year estimates still call for losses in FY2026 and FY2027, so the business has not yet been projected to turn profitable. Apyx Medical stock page

Apyx Medical Company Profile

Apyx Medical (NASDAQ: APYX) is a medical device company focused on the development and commercialization of energy-based solutions for surgical and aesthetic applications. The company’s product portfolio includes devices that utilize radiofrequency energy, cold plasma and proprietary technologies designed to deliver precise thermal control and tissue treatment. Its key offerings encompass the J-Plasma technology under the Renuvion brand, which is primarily used for subdermal skin tightening and aesthetic procedures, and its portfolio of advanced energy medical devices for general surgery, gynecology and dermatology.

Leveraging its dual focus on surgical and aesthetic markets, Apyx Medical serves physicians and healthcare providers across North America, Europe and select international regions.